Frontiers in Cardiovascular Medicine

FEBRUARY 19, 2025

Cardiovascular diseases (CVDs), characterized by a high incidence rate and high mortality, have become the leading cause of death globally. CVDs include coronary heart disease, stroke, hypertension, and peripheral vascular diseases. In China, the death rate of CVDs ranks the first in all major diseases.

Myocardial Infarction 52

Myocardial Infarction Quality of Life Heart Transplant Ischemia 52

DAIC

APRIL 30, 2024

Cardiovascular diseases are still among the top causes of death worldwide, and especially prevalent in developed countries. Myocardial infarctions , commonly known as “heart attacks,” are on the rise, resulting in a significant number of deaths each year.

Transplant 105

Transplant Heart Transplant Myocardial Infarction Heart attacks 105

Cardiology Update

APRIL 9, 2024

EMPACT-MI 1 ( NCT04509674 ) studied the effects of empagliflozin in patients who have experienced myocardial infarction (MI). Investigators assessed if empagliflozin could lower the risk of hospitalization for heart failure (HF) or death from cardiovascular disease (CVD). in the medical therapy group. Atlanta, GA.

Angina 52

Angina Myocardial Infarction Aortic valve Coronary Artery Disease 52

Journal of Clinical Investigation - Cardiology

JANUARY 16, 2025

Cardiovascular disease (CVD) remains the leading cause of morbidity and mortality worldwide, with inflammation playing a pivotal role in its pathogenesis. Understanding the intricate interplay between T cells and cardiovascular pathology is essential for developing novel immunotherapeutic strategies against CVD.

Heart Transplant 68

Heart Transplant Myocardial Infarction Transplant Cardiovascular Disease 68